March 10, 2021

Stigma: Public attitudes towards children and adults with ADHD

To gauge the extent of stigma towards persons with ADHD, a European research team hired a company specialized in market and social research to conduct a poll of some five thousand randomly selected Germans. Just over a thousand completed the interview, representing a response rate of only one in five. The team acknowledged, "Although non-responder bias has to be considered to be important, ethical considerations prohibited the collection of any detailed information on non-respondents." The sample had slightly more women and elderly persons, and a higher average level of educational attainment relative to the German population as a whole. Sampling weights we reused to compensate for these discrepancies.

The poll relied on computer-assisted telephone interviews. Interviews began with prerecorded vignettes of either an a12-year-old child or a 35-year-old adult exhibiting core symptoms of ADHD (such as "careless mistakes in schoolwork," "does not follow through on instructions," easily distracted by extraneous stimuli, "loses things", "leaves his place in the classroom or when sitting at the dining table"). Half of those interviewed were presented with child vignettes and half with adult vignettes. The gender of the person described varied randomly.

On a scale of one to five, respondents were asked to indicate levels of agreement with two statements: 1. "Basically, we are all sometimes like this person. It's just a question of how pronounced this state is." 2. "All in all, the problems of Robert / Anne are abnormal." For both child and adult vignettes, two out of three respondents agreed that "we are all sometimes like this person." One in three respondents considered the problems depicted in the child vignettes as abnormal. That dropped to one in four in the adult vignettes.

Next, respondents were asked whether they ever had a problem like this and whether someone among their family or close friends ever had to deal with such a problem. For both vignettes, one in four acknowledged having had a problem like this, and half said a close friend or family member had such a problem.

On the assumption that "negative emotional reactions are an important consequence of negative stereotypes, leading to separation, discrimination and status loss," respondents were probed for their specific emotional reactions. "I feel annoyed," " react angrily," and" provokes my incomprehension" were interpreted as indicating varying levels of anger. "Provokes fear" and "Makes me feel insecure" were seen as indicating fear. "I feel uncomfortable" was viewed as indicating somewhere between fear and anger. On the other hand, "I feel the need to help," "I feel pity," and "I feel sympathy" were interpreted as "pro-social" responses.

Pro-social reactions were by far the most common. Over two-thirds felt a need to help a child, and over half to help an adult, in such a situation. In both instances, almost half felt sympathy, and a half or more felt pity. On the other hand, a quarter of respondents in each case felt annoyed, and just under one in five felt uncomfortable. Almost one in seven reacted angrily to the child vignette, and almost one in six to the adult vignette. Fear was the least frequent emotional reaction.

In the case of adults, respondents were also asked about their willingness to accept the person described in the vignette in seven social situations:

·      Working together
·      As a neighbor
·      Marrying into the family
·      Introducing to a friend
·      Renting a room
·      Recommending for a job
·      Taking care of children

While three out of four respondents were willing to accept such persons as co-workers, only one in three would recommend them for a job. Two out of three would accept such persons as neighbors, and almost as many to marry into the family. Three out of five would very willingly introduce such persons to friends. Slightly over half would rent a room to them. But less than one in three would be willing to have such individuals take care of their children.

Older respondents were more likely to see the problems as "abnormal" and to seek greater social distance. Women, and respondents with higher levels of education, were less likely to see the problems as abnormal and more likely to respond in pro-social ways.

Though showing most Germans to be accepting of persons with ADHD, these findings still indicate a significant degree of stigma, though less than for other psychiatric conditions such as depression, schizophrenia, or alcohol dependence.

Sven Speerforck, Susanne Stolzenburg,Johannes Hertel, Hans J. Grabe, Maria Strauß, Mauro G. Carta, Matthias C.Angermeyer, Georg Schomerus, “ADHD, stigma and continuum beliefs: A population survey on public attitudes towards children and adults with attention deficit hyperactivity disorder,†Psychiatry Research (2019) DOI: https://doi.org/10.1016/j.psychres.2019.112570.  

Related posts

No items found.

What is The Pharmaceutical Supply Chain? Addressing The ADHD Medication Shortage

The persistent shortage of ADHD medications has been more than a simple annoyance for patients at the pharmacy; the inconsistent availability of these medications has had deep impacts on the daily lives of those struggling without them. While public discourse has pointed fingers at over-prescribing or at restrictive DEA quotas, a recent economic evaluation in JAMA Health Forum suggests we’ve been looking in the wrong direction for an answer to what is causing this. 

The reality of the shortage is less about increased demand and more about a fragile, globalized supply chain that snapped at a critical link. 

Debunking the "Quota Myth":

The prevailing narrative suggested that the Drug Enforcement Administration (DEA) was stifling production by refusing to raise quotas. However, the data tells a different story. In 2022, manufacturers collectively met only about 70% of their allotted production quotas. 

So we know that the problem wasn't that this DEA quota ceiling was too low. In fact, most manufacturers couldn't even reach it. Even when accounting for exports and domestic retail, production remained significantly below the legal limit. Even if the DEA had doubled its quotas, these medications still likely wouldn't have magically appeared on pharmacy shelves. 

The most striking finding in the study is the correlation between the shortage and a sharp decline in the import of raw Active Pharmaceutical Ingredients (APIs).  For the past decade, Germany has accounted for over 85% of US amphetamine imports. In 2022, these imports dropped by approximately 36.7%.  When the API doesn't arrive at the factory, production for medium and small manufacturers grinds to a halt. Unlike larger pharmaceutical giants, these smaller players often lack the inventory cushion or flexibility to quickly pivot to a new supplier. 

When the primary supply of amphetamine-based stimulants (like Adderall) faltered, it triggered a secondary crisis. Patients and clinicians, seeking alternatives, shifted toward lisdexamfetamine (Vyvanse) and methylphenidate (Ritalin/Concerta). 

  • Substitution Strain: This sudden migration of millions of patients created a domino effect, eventually leading to shortages in those medications as well. 
  • The Tolerance Gap: As any clinician knows, these stimulants are not perfect substitutes. Switching a stabilized patient to a different class of medication often leads to a trial-and-error period that may be characterized by poor tolerability or reduced efficacy. 

If we view this shortage purely through a regulatory or clinical lens, we miss the underlying cause of the crisis. The pharmaceutical industry has become a victim of its reliance on "just-in-time manufacturing” and highly concentrated sourcing.  Because over 30% of APIs for the US market are produced in just one or two facilities globally, the system isn't just inefficient; it’s brittle. We are, in a sense, trapped in a system that prioritizes cost-reduction over the resilience required for public health. 

The researchers suggest several policy shifts to prevent a repeat of this supply chain failure: 

  1. Increased Transparency: The FDA should require manufacturers to disclose their specific API suppliers. 
  1. Risk Assessment: Identifying "vulnerable" drugs that rely on fewer than three production facilities worldwide. 
  1. Regulatory Flexibility: Streamlining the process for manufacturers to switch API suppliers during a documented national shortage. 

The ADHD medication shortage wasn't a failure of clinical oversight or a sudden surge in "TikTok-driven diagnoses”, as many have suggested. It was a failure of logistics. It reminds us that the path from a lab in Germany to a patient's hand in the US is far more precarious than we realized. 

July 6, 2026

Brain Stimulation Therapy Shows No Benefit for ADHD in New Meta-analysis

ADHD is a neurodevelopmental condition rooted in delayed or atypical maturation of the prefrontal cortex  (the brain region that governs self-regulation). This maturational lag underlies the hallmark difficulties with attention, hyperactivity, and impulsivity, and also impairs what researchers call executive function: the cognitive toolkit we rely on for working memory, impulse control, mental flexibility, emotional regulation, and the ability to tolerate delays in reward. 

The Background:

Standard treatments work through two main routes. Stimulant and non-stimulant medications are considered very safe and effective treatments, but are not without risk of side effects and are not appropriate for every ADHD patient. Behavioral and psychosocial interventions can improve self-regulation and social functioning, but they require sustained effort and produce variable results. These limitations have kept the search for better alternatives active. 

One candidate that has drawn growing attention is transcranial direct current stimulation (tDCS). The technique is appealingly simple: a weak electrical current is applied to the scalp through small electrodes, modulating the excitability of neurons in the underlying cortex without requiring surgery, anesthesia, or significant discomfort. Its safety profile and ease of use have made it attractive to researchers. 

The Study: 

A newly published meta-analysis set out to give the technique its most rigorous test yet, pooling results from randomized controlled trials, including crossover designs, that compared active tDCS against sham stimulation in people with ADHD across all age groups. 

The Results: 

The findings were consistently null. Across seven trials enrolling 303 participants, tDCS produced no significant reduction in overall ADHD symptom severity compared with sham. Breaking symptoms into their components made no difference: neither hyperactivity/impulsivity nor inattention improved. Turning to executive function, 18 studies with 872 participants found no meaningful gain in inhibitory control, and 12 studies with 506 participants found the same for working memory. Smaller bodies of evidence, including three studies on cognitive flexibility (122 participants) and two on hot executive function, the motivational and emotional dimension of self-regulation (86 participants),  similarly came up empty. Variation in outcomes across studies was small to moderate, and there was no evidence of publication bias skewing the picture. 

The authors’ conclusion was succinct: tDCS was well tolerated but “did not demonstrate significant overall efficacy for core ADHD symptoms or executive functions.” 

July 2, 2026

Children and Adolescents with ADHD Face Significantly Higher Risk of Disordered Eating, Large U.S. Study Finds

Disordered eating (a broad category of persistent, harmful patterns in eating or weight control) affects between 5% and 22% of children and adolescents worldwide, with similar rates seen in the United States. The consequences are far-reaching: these conditions are linked to bone fractures, anemia, malnutrition, dental erosion, obesity, diabetes, hypertension, and elevated cholesterol and triglycerides. They also carry one of the highest mortality rates of any psychiatric illness. 

Eating disorders rarely occur in isolation. They frequently arise alongside other psychiatric and neurological conditions. Yet, until now, no large-scale study had examined these co-occurrences in a nationally representative U.S. sample. A new study addresses that gap, focusing on children and adolescents aged 6–17 and the conditions most commonly associated with disordered eating, including ADHD. 

The Study: 

Researchers drew on data from the 2022–2023 National Survey of Children's Health (NSCH), a nationally representative, cross-sectional survey covering all 50 states and Washington, D.C. Households were selected using stratified, address-based sampling, and parents or guardians completed surveys about one randomly selected child per household. The final sample included 68,000 children and adolescents. 

Results: 

After accounting for factors including sex, age, race and ethnicity, household income, educational attainment, insurance status, and household language, children and adolescents with ADHD were 2.6 times more likely to have some form of disordered eating compared to their typically developing peers. 

The elevated risk appeared across a range of specific behaviors: 

  • 60% more likely to over-exercise 
  • Twice as likely to experience a fear of vomiting or choking 
  • 2.4 times more likely to be extremely selective eaters, to skip meals, or to fast 
  • 2.7 times more likely to purge food or vomit 
  • 3 times more likely to show little interest in food 
  • 3.2 times more likely to binge eat 

A greater tendency toward using diet pills, laxatives, or diuretics was also observed in the ADHD group, though this finding did not reach statistical significance. 

The Take-Away: 

These findings underscore a need to improve both prevention and treatment strategies for disordered eating, particularly in children and adolescents who have ADHD. Clinicians working with this population are advised to screen for a wide spectrum of disordered eating behaviors.